HK Stock Market Move | ILUVATAR COREX (09903) rose by more than 5%, releasing the new generation flagship product, Tian Gai 300, a universal GPU. It also introduced a 144-core fully interconnected super-node solution.
Daysmart (09903) rose more than 5%, as of the time of writing, it was up 5.06% to HK$571.5, with a trading volume of HK$9.16 billion.
ILUVATAR COREX (09903) rose more than 5%, as of the time of publication, it has risen by 5.06% to HKD 571.5, with a turnover of HKD 9.16 billion.
On the news front, ILUVATAR COREX recently officially released the new generation general-purpose GPU flagship product, TianGe 300, at WAIC 2026, with a comprehensive upgrade around chip architecture, key operators, system expansion, and software ecology to benchmark and surpass the performance of the Hopper architecture, providing high-quality computing power support for AI scale applications. In addition, the company's simultaneous launch of the 144-core all-interconnect super node solution has entered into cooperation advancement with multiple potential customers.
Sinolink's recent research report pointed out that the company is continuously advancing the TianGe series upgrade, and the successive launch of the new generation of products is expected to continuously enhance computing power, bandwidth, and cluster capabilities, shortening the window period between product generations; In 2025, the TianGe training and Zhikai reasoning series shipments increased by 131.5% and 194.8% respectively year-on-year. The company is synchronously developing the next generation of training and reasoning products, and the new generation of Zhikai focuses on strengthening low precision and mixed precision computing capabilities, further taking on the needs for cost reduction and efficiency improvement in large model reasoning and localization; The Tongyang series extends the company's product boundaries from cloud GPU to edge computing power, opening up long-term incremental space for intelligent development in the physical world.
Related Articles

Zhejiang Jianfeng Group's subsidiary, which produces injectable special citicoline, has obtained a drug registration certificate.

New Stock Outlook | With a 10-fold increase in revenue and over 900 million dollars in losses over the past three years, when will Zhendrive Technology's economies of scale lead to a turning point in profitability?

Zhejiang Conba Pharmaceutical (600572.SH) subsidiary's musk tongxin pill new indication clinical trial application approved.
Zhejiang Jianfeng Group's subsidiary, which produces injectable special citicoline, has obtained a drug registration certificate.

New Stock Outlook | With a 10-fold increase in revenue and over 900 million dollars in losses over the past three years, when will Zhendrive Technology's economies of scale lead to a turning point in profitability?

Zhejiang Conba Pharmaceutical (600572.SH) subsidiary's musk tongxin pill new indication clinical trial application approved.

RECOMMEND





